{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:00:09Z","timestamp":1790222409058,"version":"4.1.0"},"reference-count":42,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":3426,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neoplasia (PanIN). Treatment with the glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks induced the expansion of PDGs with mucinous metaplasia and columnar cell atypia resembling low-grade PanIN in rats. In the pancreata of Pdx1-Cre; LSL-KrasG12D mice, exendin-4 led to acceleration of the disruption of exocrine architecture and chronic pancreatitis with mucinous metaplasia and increased formation of murine PanIN lesions. PDGs and PanIN lesions in rodent and human pancreata express the GLP-1 receptor. Exendin-4 induced proproliferative signaling pathways in human pancreatic duct cells, cAMP\u2013protein kinase A and mitogen-activated protein kinase phosphorylation of cAMP-responsive element-binding protein, and increased cyclin D1 expression. These GLP-1 effects were more pronounced in the presence of an activating mutation of Kras and were inhibited by metformin. These data reveal that GLP-1 mimetic therapy may induce focal proliferation in the exocrine pancreas and, in the context of exocrine dysplasia, may accelerate formation of neoplastic PanIN lesions and exacerbate chronic pancreatitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/db11-1109","type":"journal-article","created":{"date-parts":[[2012,1,21]],"date-time":"2012-01-21T02:53:19Z","timestamp":1327114399000},"page":"1250-1262","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":226,"title":["Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model"],"prefix":"10.2337","volume":"61","author":[{"given":"Belinda","family":"Gier","sequence":"first","affiliation":[{"name":"Larry L. Hillblom Islet Research Center, University of California Los Angeles (UCLA), David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksey V.","family":"Matveyenko","sequence":"additional","affiliation":[{"name":"Larry L. Hillblom Islet Research Center, University of California Los Angeles (UCLA), David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kirakossian","sequence":"additional","affiliation":[{"name":"Larry L. Hillblom Islet Research Center, University of California Los Angeles (UCLA), David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dawson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, UCLA, David Geffen School of Medicine, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center, UCLA, David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Dry","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, UCLA, David Geffen School of Medicine, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center, UCLA, David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Butler","sequence":"additional","affiliation":[{"name":"Larry L. Hillblom Islet Research Center, University of California Los Angeles (UCLA), David Geffen School of Medicine, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center, UCLA, David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2012,4,13]]},"reference":[{"key":"2022031223452978900_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/dmr.5610030101","article-title":"Gastrointestinal peptides and insulin secretion","volume":"3","author":"Ebert","year":"1987","journal-title":"Diabetes Metab Rev"},{"key":"2022031223452978900_B2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.diabres.2005.11.007","article-title":"GLP-1\/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts","volume":"73","author":"Xu","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031223452978900_B3","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2337\/db09-0058","article-title":"Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin","volume":"58","author":"Matveyenko","year":"2009","journal-title":"Diabetes"},{"key":"2022031223452978900_B4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"2022031223452978900_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-291X(02)00359-5","article-title":"Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective","volume":"294","author":"Deacon","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"2022031223452978900_B6","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031223452978900_B7","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/diacare.26.8.2370","article-title":"Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and\/or sulfonylurea treatment in patients with type 2 diabetes","volume":"26","author":"Fineman","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031223452978900_B8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"2022031223452978900_B9"},{"key":"2022031223452978900_B10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4158\/EP09104.CRR","article-title":"Exenatide-induced acute pancreatitis","volume":"16","author":"Ayoub","year":"2010","journal-title":"Endocr Pract"},{"key":"2022031223452978900_B11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide: the FDA\u2019s review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031223452978900_B12"},{"key":"2022031223452978900_B13","article-title":"Sitagliptin (marketed as Januvia and Janumet): acute pancreatitis","author":"U.S. Food and Drug Administration, Department of Health and Human Services","year":"2009"},{"key":"2022031223452978900_B14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1463-1326.2011.01376.x","article-title":"A cohort study of acute pancreatitis in relation to exenatide use","volume":"13","author":"Dore","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031223452978900_B15","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1210\/endo.141.12.7806","article-title":"Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats","volume":"141","author":"Perfetti","year":"2000","journal-title":"Endocrinology"},{"key":"2022031223452978900_B16","first-page":"153","article-title":"Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas","volume-title":"Diabetologia","author":"Nachnani","year":"2009"},{"key":"2022031223452978900_B17","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db09-0626","article-title":"Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice","volume":"58","author":"Koehler","year":"2009","journal-title":"Diabetes"},{"key":"2022031223452978900_B18","first-page":"E1076","article-title":"Exenatide does not evoke pancreatitis and attenuates chemically-induced pancreatitis in normal and diabetic rodents","volume-title":"Am J Physiol Endocrinol Metab","author":"Tatarkiewicz","year":"2010"},{"key":"2022031223452978900_B19","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1053\/j.gastro.2009.12.005","article-title":"Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia","volume":"138","author":"Strobel","year":"2010","journal-title":"Gastroenterology"},{"key":"2022031223452978900_B20","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young","year":"1999","journal-title":"Diabetes"},{"key":"2022031223452978900_B21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","article-title":"Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse","volume":"4","author":"Hingorani","year":"2003","journal-title":"Cancer Cell"},{"key":"2022031223452978900_B22","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","author":"Gier","journal-title":"J Clin Endocrinol Metab."},{"key":"2022031223452978900_B23","first-page":"1689","article-title":"Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D\/Pdx1-Cre mice","volume-title":"Carcinogenesis","author":"Bai","year":"2011"},{"key":"2022031223452978900_B24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/0008-5472.CAN-05-2168","article-title":"Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations","volume":"66","author":"Hruban","year":"2006","journal-title":"Cancer Res"},{"key":"2022031223452978900_B25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/gut.2009.188961","article-title":"The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer","volume":"59","author":"Fendrich","year":"2010","journal-title":"Gut"},{"key":"2022031223452978900_B26","first-page":"1763","article-title":"Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16","volume":"148","author":"Furukawa","year":"1996","journal-title":"Am J Pathol"},{"key":"2022031223452978900_B27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0002-9440(10)64800-6","article-title":"Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype","volume":"157","author":"Ouyang","year":"2000","journal-title":"Am J Pathol"},{"key":"2022031223452978900_B28","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1158\/0008-5472.CAN-04-3208","article-title":"In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis","volume":"65","author":"Qian","year":"2005","journal-title":"Cancer Res"},{"key":"2022031223452978900_B29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1158\/1541-7786.MCR-08-0577","article-title":"K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways","volume":"7","author":"Matsuo","year":"2009","journal-title":"Mol Cancer Res"},{"key":"2022031223452978900_B30","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1101\/gad.1097103","article-title":"cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2","volume":"17","author":"Jhala","year":"2003","journal-title":"Genes Dev"},{"key":"2022031223452978900_B31","doi-asserted-by":"crossref","first-page":"32517","DOI":"10.1074\/jbc.M301174200","article-title":"Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells","volume":"278","author":"Arnette","year":"2003","journal-title":"J Biol Chem"},{"key":"2022031223452978900_B32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1677\/joe.1.06160","article-title":"Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways","volume":"188","author":"Friedrichsen","year":"2006","journal-title":"J Endocrinol"},{"key":"2022031223452978900_B33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/dc09-1902","article-title":"GLP-1-based therapy for diabetes: what you do not know can hurt you","volume":"33","author":"Butler","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031223452978900_B34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-009-1556-8","article-title":"Pancreatic duct replication is increased with obesity and type 2 diabetes in humans","volume":"53","author":"Butler","year":"2010","journal-title":"Diabetologia"},{"key":"2022031223452978900_B35","first-page":"150","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume-title":"Gastroenterology","author":"Elashoff","year":"2011"},{"key":"2022031223452978900_B36","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","article-title":"Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031223452978900_B37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s11695-008-9599-3","article-title":"Obesity, pancreatitis, and pancreatic cancer","volume":"18","author":"Gumbs","year":"2008","journal-title":"Obes Surg"},{"key":"2022031223452978900_B38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2009.04.013","article-title":"Antidiabetic therapies affect risk of pancreatic cancer","volume":"137","author":"Li","year":"2009","journal-title":"Gastroenterology"},{"key":"2022031223452978900_B39","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"2022031223452978900_B40","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2010.02382.x","article-title":"Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis","volume":"64","author":"Engel","year":"2010","journal-title":"Int J Clin Pract"},{"key":"2022031223452978900_B41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000178874","article-title":"Pancreatic intraepithelial neoplasia revisited and updated","volume":"9","author":"Sipos","year":"2009","journal-title":"Pancreatology"},{"key":"2022031223452978900_B42","first-page":"306","article-title":"Update on pancreatic intraepithelial neoplasia","volume":"1","author":"Hruban","year":"2008","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/61\/5\/1250\/568878\/1250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/61\/5\/1250\/568878\/1250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:28:08Z","timestamp":1667392088000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/61\/5\/1250\/33797\/Chronic-GLP-1-Receptor-Activation-by-Exendin-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,13]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,4,13]]},"published-print":{"date-parts":[[2012,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db11-1109","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,13]]}}}